Sign in

    Joanne Lee • Maxim Group

    No verifiable information about Joanne Lee as an analyst at Maxim Group could be found from public sources or LinkedIn profile data. There is no evidence of her covering specific companies, holding a formal title, or being ranked on platforms such as TipRanks. Credentials, performance metrics, and a career timeline are not available, and there are no indications of FINRA registration or securities licenses related to Maxim Group. As such, her professional details at Maxim Group remain unconfirmed.

    Joanne Lee's questions to Bionano Genomics Inc (BNGO) leadership

    Joanne Lee's questions to Bionano Genomics Inc (BNGO) leadership • Q1 2025

    Question

    On behalf of Jason McCarthy, Joanne Lee asked about the specific steps Bionano is taking to increase Saphyr system utilization among its existing routine users.

    Answer

    CEO Robert Holmlin detailed a three-part strategy to boost utilization. First, driving adoption and proficiency with the AI-powered VIA software to increase lab capacity. Second, supporting menu expansion by helping labs adopt OGM for new applications, such as multiple myeloma, based on recent publications. Third, ensuring overall customer proficiency with the unique OGM workflow through dedicated support from the company's largest internal organization.

    Ask Fintool Equity Research AI

    Joanne Lee's questions to Acurx Pharmaceuticals Inc (ACXP) leadership

    Joanne Lee's questions to Acurx Pharmaceuticals Inc (ACXP) leadership • Q1 2025

    Question

    Joanne Lee of Maxim Group inquired about Acurx's plans to leverage recent publications on ibezapolstat's selective activity and microbiome-preserving effects, asking if these findings would influence the Phase III trial design or lead to new microbiome-related endpoints.

    Answer

    President and CEO David Luci confirmed that microbiome preservation is already a secondary endpoint for the Phase III trial. He highlighted this as a key differentiator explaining lower C. diff recurrence rates and mentioned the company is internally exploring alternative regulatory pathways based on these strong mechanistic data.

    Ask Fintool Equity Research AI

    Joanne Lee's questions to Matinas BioPharma Holdings Inc (MTNB) leadership

    Joanne Lee's questions to Matinas BioPharma Holdings Inc (MTNB) leadership • Q2 2024

    Question

    Joanne Lee of Maxim Group, on behalf of Jason McCarthy, requested a review of the key design elements and objective measures for the upcoming ORALTO Phase III non-inferiority study for MAT2203.

    Answer

    CEO Jerome Jabbour first clarified that a definitive partnership agreement is a goal but not yet a secured milestone. Dr. Theresa Matkovits then detailed the ORALTO trial design, explaining it is a two-arm, non-inferiority study comparing MAT2203 to IV liposomal amphotericin B in patients with invasive aspergillosis who have limited treatment options. The primary endpoint is all-cause mortality at 6 weeks, with key secondary endpoints including safety, global response at 12 weeks, and pharmacoeconomic impact.

    Ask Fintool Equity Research AI

    Joanne Lee's questions to Brainstorm Cell Therapeutics Inc (BCLI) leadership

    Joanne Lee's questions to Brainstorm Cell Therapeutics Inc (BCLI) leadership • Q2 2024

    Question

    Joanne Lee, on behalf of Jason McCarthy, inquired about the CMC alignment with the FDA, asking if any new actions were required. She also requested details on the revised ALSFRS entry criteria for the upcoming Phase IIIb study and the mechanistic rationale for why these changes might better identify NurOwn's therapeutic effect.

    Answer

    Executive Chaim Lebovits confirmed that alignment with the FDA was reached to enable trial initiation. Executive Ibrahim Dagher elaborated on the new trial criteria, explaining that patients must have scores of 2, 3, or 4 on all 12 items of the ALSFRS score, with a total score of 45 or less. He stated these changes, combined with other criteria like slow vital capacity above 65%, are designed to enroll patients earlier in their disease progression, a population where NurOwn is expected to show the most benefit.

    Ask Fintool Equity Research AI